23
Treatment, outcome and plans for the final phase Dr Barbara A Gregson Trial Director

Treatment, outcome and plans for the final phase

Embed Size (px)

DESCRIPTION

Treatment, outcome and plans for the final phase. Dr Barbara A Gregson Trial Director. Treatments. Study Flow Chart. Initial Conservative Treatment. Early Surgery. Diagnostic CT. Equipoise. Consent to STICH II. Telephone randomisation service (24 hours) or web service. - PowerPoint PPT Presentation

Citation preview

Page 1: Treatment, outcome and plans for the final phase

Treatment, outcome and plans for the final phase

Dr Barbara A Gregson

Trial Director

Page 2: Treatment, outcome and plans for the final phase

Treatments

Page 3: Treatment, outcome and plans for the final phase

Study Flow Chart

• 5 Days GCS Monitoring• Day 5 CT • Discharge / 2 week form

6 month outcome questionnaire

Diagnostic CT

Equipoise

Consent to STICH II

Telephone randomisation service (24 hours) or web service

Initial Conservative Treatment

Early Surgery

Page 4: Treatment, outcome and plans for the final phase

STICH II - treatments

• Early surgery– Craniotomy performed as soon as possible

(within 12 hours)– Best medical treatment

• Initial conservative treatment– Best medical treatment– Delayed evacuation if patient deteriorates and

it becomes clinically appropriate

Page 5: Treatment, outcome and plans for the final phase

Compliance with treatment allocation: surgery group

• Of those randomised to surgery:

- 43% had surgery in under 3 hours- 27% had surgery between 3-6 hours- 21% had surgery between 6-12 hours- 4% had surgery in over 12 hours- 6% did not have surgery

Page 6: Treatment, outcome and plans for the final phase

Compliance with treatment allocation: conservative group

• Of those randomised to initial conservative treatment:– 20% had surgery.

• Of those having surgery:– 32% had surgery in under 12 hours (6% of

total)

Page 7: Treatment, outcome and plans for the final phase

Outcomes

Page 8: Treatment, outcome and plans for the final phase

Outcome measurement

• Confirm patient’s status (any major adverse events) and address

• Six month structured postal questionnaire sent by STICH Office to patient for completion by patient or carer– Primary

• Extended GOS– Secondary

• Rankin• EuroQol• Residence• Focal deficits• Other problems

• Analysis by intention to treat

Page 9: Treatment, outcome and plans for the final phase

Outcome for first 350 patients

• 6 month primary outcome data obtained for 329 (94%) patients (20/04/2011)

• 75 died (23%), • 254 completed postal questionnaires were returned. • 3 patients have withdrawn following randomisation.

• Residence at 6 months – 9% living at home alone 23% with Severe Disability– 78% living with family 51% with SD– 13% in residential/nursing homes 60% with SD in residential

88% with SD in nursing homes.

Page 10: Treatment, outcome and plans for the final phase

Modified Rankin Scale at six months

Page 11: Treatment, outcome and plans for the final phase

Glasgow Outcome Scale at six months

Page 12: Treatment, outcome and plans for the final phase

Outcome and age

Page 13: Treatment, outcome and plans for the final phase

Outcome and volume of haematoma

Page 14: Treatment, outcome and plans for the final phase

Outcome and GCS

Page 15: Treatment, outcome and plans for the final phase

Plans for the final phase

Page 16: Treatment, outcome and plans for the final phase

Recruitment rate over time

Six month period patients recruited during period

centre-months of recruitment

patients per centre per month

Dec 06 – May 07 8 20 0.4

June 07 – Nov 07 18 111 0.162

Dec 07 – May 08 32 204 0.157

June 08 – Nov 08 45 314 0.143

Dec 08 – May 09 66 417 0.158

June 09 – Nov 09 71 462 0.154

Dec 09 – May 10 68 515 0.132

June 10 – Nov 10 71 560 0.127

Page 17: Treatment, outcome and plans for the final phase

Recruitment pattern by month- up to 31 March 2011

Page 18: Treatment, outcome and plans for the final phase

Recruitment pattern by quarter- up to 31 March 2011

Page 19: Treatment, outcome and plans for the final phase

Review of progress towards final recruitment target

Target total

Planned recruitment (Extension 29/08/08)

Actual recruitment

Planned recruitment (Dec 2009 to bring on target)

Assuming 15 per month

Assuming 12 per month

Area enlarged in following slide

Page 20: Treatment, outcome and plans for the final phase

Review of progress towards final recruitment target

Target total

Planned recruitment (Extension 29/08/08)

Actual recruitment

Planned recruitment (Dec 2009 to bring on target)

Assuming 15 per month

Assuming 12 per month

Page 21: Treatment, outcome and plans for the final phase

Publications

Page 22: Treatment, outcome and plans for the final phase

Conclusions

• Crossover rates are lower than in STICH but could be lower still.

• Ongoing six month follow up rate is 94%.

• 34% of patients make either a good recovery or have moderate disability according to the Glasgow Outcome Scale.

• To attain our target of 600 patients centres need to continue to develop their patient screening strategies and increase their recruitment rates.

• All sites who recruit patients will be acknowledged in the publication of the final results.

Page 23: Treatment, outcome and plans for the final phase

To join the study contact:•

• Website: www.research.ncl.ac.uk/stich

• Email: [email protected]

• Tel: +44 191 222 5761• Fax: +44 191 222 5762

• Address: Neurosurgical Trials Unit

Newcastle University

3-4 Claremont Terrace

Newcastle upon Tyne

NE2 4AEDepartment of Health Disclaimer: The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Department of Health.